# Who Loses More Weight on a GLP-1?

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/who-loses-more-weight-on-a-glp1

> Across 64 randomized trials, the only subgroup difference was sex: women lost 10.9% against 6.8% for men. Age, race, ethnicity, starting BMI and starting HbA1c made no significant difference.

## Key points

- Women lost 10.9% of body weight, men 6.8%, across 6 trials and 19,906 patients.
- No significant difference by age, race, ethnicity, starting BMI or starting HbA1c.
- The HbA1c 'no difference' rests on 4 trials, which is weak evidence of no difference.
- Women weigh less on average, so the same loss in kilograms is a larger percentage of their weight.

“Will it work for someone like me?” is the question underneath most of what people read about these drugs. A systematic review pooled **64 randomized trials** to answer it, and found essentially one difference: women lost more than men. Age, race, ethnicity, starting BMI and starting blood sugar made no significant difference.[1]

## What differed, and what did not

Across six trials covering 19,906 patients analyzed by sex, weight loss was **10.9%** among women (95% CI 7.0 to 14.8) against **6.8%** among men (95% CI 4.6 to 9.0).[1]

*Subgroups examined for differences in treatment effect. From a review of 41 articles representing 64 randomized trials.*

| Subgroup | Trials analyzable | Difference found |
| --- | --- | --- |
| Sex | 6 (19,906 patients) | **Yes** — 10.9% vs 6.8% |
| Age | 7 (4,314) | None significant |
| Race | 9 (25,229) | None significant |
| Ethnicity | 7 (8,328) | None significant |
| Baseline BMI | 15 (9,473) | None significant |
| Baseline HbA1c | 4 (1,886) | None significant |

## Why the empty column is the useful one

Most coverage of these drugs is built on the assumption that response varies enormously and that the trick is finding your personal angle. This review suggests the opposite: the drug behaves about the same across the characteristics people most often worry about. A separate tirzepatide analysis found the same for [obesity that began before age 25](https://glpwatchdog.org/research/does-a-lifetime-of-it-change-anything), which responded much like obesity that began later.

> Across 15 trials and 9,473 patients, starting BMI made no significant difference to how much weight was lost.

One caveat arrived after this was written. A large real-world cohort did find outcomes differing by race and ethnicity, which we take apart in [who responds in the real world](https://glpwatchdog.org/research/who-responds-in-the-real-world). In short, trials equalize cost, supply and dose escalation, and ordinary care does not, so the gap lies in the conditions rather than in the patients. Keep that in mind before you pay for a program built around personalization, along with a second point: a group average cannot tell you what one person will lose. Consistency across subgroups is not the same as consistency between people, and individual variation within every one of those groups remains large.

## How much weight the nulls can carry

Less than the headline implies, and the review is transparent about it. Look at the middle column of that table again: the HbA1c conclusion rests on four trials and 1,886 patients. That is a weak basis for “no difference”, and it is not the same as evidence that no difference exists.

- **Absence of a detected difference is not proof of sameness**, especially in the smaller analyses.
- **Subgroup analysis is exploratory by nature** even when pre-specified, because trials are powered for their main outcome and not for slices of it.
- **Reporting was uneven.** Baseline BMI was examined in 75% of the trials, sex in only 21%, so the subgroups that matter most to individual readers are the least studied.

## About the sex difference specifically

The difference is real in this analysis, and it is easy to over-interpret. Percentage weight loss is not a pure measure of drug response. Women on average weigh less than men, so the same absolute loss registers as a larger percentage. Differences in body composition and in dosing relative to body size also feed into that gap.

What the trials show is that women lost a larger share of their body weight, and the reasons are not established. That does not show the drug works better in women in any mechanistic sense, and nobody should choose or avoid treatment on the basis of it. Women also report more nausea and hair loss; the side-effect numbers by sex are in [GLP-1 side effects in women vs men](https://glpwatchdog.org/research/glp1-side-effects-in-women-vs-men). When it comes to choosing a seller, our semaglutide boards [for women](https://glpwatchdog.org/best/semaglutide-providers/for-women) and [for men](https://glpwatchdog.org/best/semaglutide-providers/for-men) print this split beside the ranking.

## Frequently asked questions

### Do GLP-1 drugs work better for some people than others?

Across 64 randomized trials, the only subgroup difference detected was by sex: women lost 10.9% of body weight against 6.8% for men. No significant differences appeared by age, race, ethnicity, starting BMI or starting HbA1c.

### Does starting heavier mean losing more?

Not on this evidence. Fifteen trials covering 9,473 patients found no significant difference in treatment effect by baseline BMI, measured as kilograms lost.

### Why did women lose more?

The reasons are not established, and percentage weight loss is not a pure measure of drug response. Women on average weigh less than men, so an equal absolute loss registers as a larger percentage. Body composition and dosing relative to body size also contribute.

### Does age affect how well it works?

No significant difference was found across seven trials covering 4,314 patients. That is a relatively small evidence base for a conclusion of no difference, so it is better read as an absence of any signal than as proof that age is irrelevant.

### So can I expect the average result?

Consistency across subgroups is not the same as consistency between individuals. Variation within every one of these groups remains large, and a group mean cannot tell you what will happen to any one person.

## References

1. Alexander GC, Xiao X, Dilek S, et al. Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis. JAMA Internal Medicine. 2026. PMID: 41770554. https://pubmed.ncbi.nlm.nih.gov/41770554/

---

Cite as: GLP Watchdog, Nora Bissett, "Who Loses More Weight on a GLP-1?", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/who-loses-more-weight-on-a-glp1

Canonical HTML page: https://glpwatchdog.org/research/who-loses-more-weight-on-a-glp1

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
